Tumor-specific neoantigens play the main role for developing personal vaccines in 13 cancer immunotherapy. We propose, for the first time, a personalized de novo sequencing 14 workflow to identify HLA-I and HLA-II neoantigens directly and solely from mass spectrometry 15 data. Our workflow trains a personal deep learning model on the immunopeptidome of an 16
INTRODUCTION 26
Neoantigens are tumor-specific mutated peptides that are brought to the surface of tumor cells 27 by major histocompatibility complex (MHC) proteins and can be recognized by T cells as 28
"foreign" (non-self) to trigger immune response. As neoantigens carry tumor-specific mutations 29
and are not found in normal tissues, they represent ideal targets for the immune system to 30 distinguish cancer cells from non-cancer ones [1] [2] [3] . The potential of neoantigens for cancer 31 vaccines is supported by multiple evidences, including the correlation between mutation load 32 and response to immune checkpoint inhibitor therapies [4, 5] , neoantigen-specific T cell 33 responses detected even before vaccination (naturally occurring) [6] [7] [8] . Indeed, three 34 independent studies have further demonstrated successful clinical trials of personalized 35
neoantigen vaccines for patients with melanoma [6-8]. The vaccination was found to reinforce 36
pre-existing T cell responses and to induce new T cell populations directed at the neoantigens. 37
In addition to developing cancer vaccines, neoantigens may help to identify targets for adoptive 38 T cell therapies, or to improve the prediction of response to immune checkpoint inhibitor 39 therapies. 40
And thus began the "gold rush" for neoantigen mining [1] [2] [3] . The current prevalent approach to 41 identify candidate neoantigens often includes two major phases: (i) exome sequencing of 42 cancer and normal tissues to find somatic mutations and (ii) predicting which mutated peptides 43
are most likely to be presented by MHC proteins for T cell recognition. The first phase is 44 strongly backed by high-throughput sequencing technologies and bioinformatics pipelines that 45 have been well established through several genome sequencing projects during the past 46
decade. The second phase, however, is still facing challenges due to our lack of knowledge of 47 the MHC antigen processing pathway: how mutated proteins are processed into peptides; how 48 those peptides are delivered to the endoplasmic reticulum by the transporter associated with 49 antigen processing; and how they bind to MHC proteins. To make it further complicated, human 50 leukocyte antigens (HLA), those genes that encode MHC proteins, are located among the most 51
genetically variable regions and their alleles basically change from one individual to another. 52
The problem is especially more challenging for HLA class II (HLA-II) peptides than HLA class I 53 (HLA-I), because the former are longer, their motifs have greater variations, and very limited 54 data is available. 55
Current in silico methods focus on predicting which peptides bind to MHC proteins given the 56 HLA alleles of a patient, e.g. NetMHC [9, 10]. However, usually very few, less than a dozen from 57 thousands of predicted candidates are confirmed to be presented on the tumor cell surface and 58 even less are found to trigger T cell responses, not to mention that real neoantigens may not be 59 among top predicted candidates [1, 2] . Several efforts have been made to improve the MHC 60 binding prediction, including using mass spectrometry data in addition to binding affinity data for 61 more accurate prediction of MHC antigen presentation [11, 12] . Recently, proteogenomic 62 approaches have been proposed to combine mass spectrometry and exome sequencing to 63 identify neoantigens directly isolated from MHC proteins, thus overcoming the limitations of 64 MHC binding prediction [13, 14] . In those approaches, exome sequencing was performed to 65 build a customized protein database that included all normal and mutated protein sequences. 66
The database was further used by a search engine to identify endogenous peptides, including 67
neoantigens, that were obtained by immunoprecipitation assays and mass spectrometry. 68
Existing database search engines, however, are not designed for HLA peptides and may be 69
biased towards tryptic peptides [15, 16] . They may have sensitivity and specificity issues when 70 dealing with a very large search space created by (i) all mRNA isoforms from exome 71 sequencing and (ii) unknown digestion rules for HLA peptides. Furthermore, recent 72
proteogenomic studies reported a weak correlation between proteome-and genome-level 73 mutations, where the number of identified mutated HLA peptides was three orders of 74 magnitudes less than the number of somatic mutations that were provided to the database 75 search engines [13, 14] . A large number of genome-level mutations were not presented at the 76 proteome level, while at the same time, some mutated peptides might be difficult to detect at the 77 genome level. For instance, Faridi et al. found evidence of up to 30% of HLA-I peptides that 78
were cis-and trans-splicing, which couldn't be detected by exome sequencing nor protein 79 database search [25] . Thus, an independent approach that does not rely heavily on genome-80 level information to identify mutated peptides directly from mass spectrometry data is needed, 81
and de novo sequencing is the key to address this problem. 82
In this study, we propose, for the first time, a personalized de novo sequencing workflow to 83 identify HLA-I and HLA-II neoantigens directly and solely from mass spectrometry data. De novo 84
sequencing is invented for the purpose of discovering novel peptides and proteins, genetic 85 variants or mutations. Thus, its application to identify neoantigens is a perfect match. We bring 86 de novo sequencing to the "personalized" level by training a specific machine learning model for 87 each individual patient using his/her own data. In particular, we use the collection of normal HLA 88 peptides, i.e. the immunopeptidome, of a patient to train a model and then use it to predict 89 mutated HLA peptides of that patient. Learning an individual's immunopeptidome is made 90 possible by our recent deep learning model, DeepNovo [17, 18] , which uses a long-short-term 91 memory (LSTM) recurrent neural network (RNN) to capture sequence patterns in peptides or 92 proteins, in a similar way to natural languages [19] . This personalized learning workflow 93 significantly improves the accuracy of de novo sequencing for comprehensive and reliable 94 identification of neoantigens. Furthermore, our de novo sequencing approach predicts peptides 95 solely from mass spectrometry data and does not depend on genomic information as existing 96
approaches. We applied the workflow to datasets of five melanoma patients and successfully 97 identified in average 154 HLA-I and 47 HLA-II candidate neoantigens per patient, including 98
those with validated T cell responses and those novel neoantigens that had not been reported in 99 previous studies. 100
RESULTS 101
Personalized De novo Sequencing of Individual Immunopeptidomes 102 in Supplementary Table S1 for illustration. 108
In step 1 of the workflow, to build the immunopeptidome of the patient, we searched the mass 109 spectrometry data against the standard Swiss-Prot human protein database. As digestion rules 110
for HLA peptides are unknown, a search engine that supports no-enzyme-specific digestion is 111 needed (we used PEAKS X [18]). Identified normal HLA peptides and their peptide-spectrum 112 matches (PSMs) at 1% false discovery rate (FDR) represent the patient's immunopeptidome 113
and its spectral library. Mutated HLA peptides were not presented in the protein database, so 114 their spectra remained unlabeled. For example, we identified 341,216 PSMs of 35,551 HLA-I 115 peptides and 67,021 PSMs of 9,664 HLA-II peptides from Mel-15 datasets. The numbers of 116 unlabeled spectra were 596,915 and 135,490, respectively ( Supplementary Table S1 ). 117
In step 2, we used the identified normal HLA peptides and their PSMs to train DeepNovo, a 118 neural network model for de novo peptide sequencing [17, 18] . In addition to capturing fragment 119 ions in tandem mass spectra, DeepNovo learns sequence patterns of peptides by modelling 120 them as a special language with an alphabet of 20 amino acid letters. This unique advantage 121 allowed us to train a personalized model to adapt to a specific immunopeptidome of an 122
individual patient and achieved much better accuracy than a generic model (results are shown 123 in a later section). At the same time, it was essential to apply counter-overfitting techniques so 124 that the model could predict new peptides that it had not seen during training. We partitioned the 125
PSMs into training, validation, and test sets (ratio 90-5-5, respectively) and restricted them not 126
to share common peptide sequences. We stopped the training process if there was no 127 improvement on the validation set and evaluated the model performance on the test set. As a 128
result, our personalized model was able to both achieve very high accuracy on an individual 129 immunopeptidome and detect mutated peptides. This approach is particularly useful for 130 missense mutations (the most common source of neoantigens) because they still preserve most 131 patterns in the peptide sequences. 132
In step 3, we used the personalized DeepNovo model to perform de novo peptide sequencing 133 on both labeled spectra (i.e., the PSMs identified in step 1) and unlabeled spectra. Results from 134 labeled spectra were needed for accuracy evaluation and calibrating prediction confidence 135
scores. Peptides identified from unlabeled spectra and not presented in the protein database 136
were defined as "de novo peptides" and would be further analyzed in the next steps to find 137 candidate neoantigens of interest. 138
In step 4, a quality control procedure was designed to select high-confidence de novo peptides 139
and to estimate their FDR. We first calculated the accuracy of de novo sequencing on the test 140 set of PSMs by comparing the predicted peptide to the true one for each spectrum. DeepNovo 141 also provides a confidence score for each predicted peptide, which can be used as a filter for 142 better accuracy. Since the test set did not share common peptides with the training set, we 143
expected the distribution of accuracy versus confidence score on the test set to be close to that 144 of de novo peptides which the model had not seen during training. Thus, we calculated a score 145 threshold at a precision of 95% on the test set and used it to select high-confidence de novo 146 peptides ( Figure 2b ). Finally, to estimate the FDR of high-confidence de novo peptides, we 147 performed a second-round PEAKS X search of all spectra against a combined list of those 148 peptides and the database peptides (i.e. normal HLA peptides identified in step 1). Only de novo 149 peptides identified at 1% FDR were retained. Thus, our stringent procedure of quality control 150 guaranteed that each de novo peptide was supported by solid evidences from two independent 151 tools, DeepNovo and PEAKS X. For instance, we found 16,226 HLA-I and 2,717 HLA-II high-152
confidence de novo peptides from Mel-15 datasets. Among them, 5,320 HLA-I and 863 HLA-II 153 de novo peptides passed 1% FDR filter ( Supplementary Table S1 ). 154
We applied this workflow to train personalized models for another four patients and to predict 155 their HLA-I and HLA-II de novo peptides. score distribution in Figure 2b . At the same level of amino acid accuracy, e.g. 95%, the 175 personalized model required a lower score cutoff, thus allowing more de novo peptides to be 176
identified. Indeed, Figure 1c shows that the personalized model identified 87.8% more high-177
confidence de novo peptides (16,226 / 8,642 = 1.878) and 38.9% more de novo peptides at 1% 178 FDR (5,320 / 3,829 = 1.389). More importantly, the personalized model was able to capture 6 of 179 8 target neoantigens of patient Mel-15 (Table 2) , while the generic model only recovered 3 of 180
them. Those results demonstrate that our personalized approach substantially improves the 181 accuracy and identification rate of de novo peptides by adapting to a specific immunopeptidome 182
of an individual patient. 183
Analysis of Immune Characteristics of De novo HLA peptides 184
In this section, we studied common immune features of de novo HLA peptides and compared 185 them to normal HLA peptides, i.e. those identified by the database search engine in step 1 of 186 the workflow. We also compared to previously reported human epitopes from the Immune 187
Epitope Database (IEDB) [20] . 188 peptides of five patients are provided in Supplementary Table S2 . 193
Next, we compared de novo and database HLA-I peptides of patient Mel-15 to 18,022 IEDB 194 epitopes, which were retrieved according to the patient's six alleles (HLA-A03:01, HLA-A68:01, 195
HLA-B27:05, HLA-B35:03, HLA-C02:02, HLA-C04:01). The Venn diagram in Figure 2e shows 196 that 56 de novo peptides have been reported as epitopes in earlier studies. Note that the de 197 novo peptides were specific to an individual patient and were not presented in the protein 198 database, so the chance to find them in IEDB is rare. Even 81.4% (28,943 / 35,551) of the 199 database peptides were not found in IEDB. This is due to the large variation of HLA peptides 200 and further emphasizes the importance of our personalized approach. Figure 2e further shows 201 that both de novo and database peptides have the same characteristic length distribution as 202
IEDB epitopes. For the other four patients Mel-5, Mel-8, Mel-12, and Mel-16, we also found that 203 the length distributions of their de novo HLA-I peptides are very similar to those of database 204 peptides ( Supplementary Figures S1a-d ). However, for HLA-II, the de novo peptides tend to be 205 longer than the database ones ( Supplementary Figures S1e, f) . We hypothesize that it might be 206 challenging for the database search engine to identify long HLA-II peptides when the digestion 207 rule is unknown. 208
One of the most widely used measures to assess HLA peptides is their binding affinity to MHC 209
proteins. We used NetMHCpan [10] to predict the binding affinity of the de novo, database, and 210
IEDB peptides for HLA-I alleles of patient Mel-15. Figures 2g shows that the de novo peptides 211
have the same level of binding affinity as database and IEDB peptides (p-value > 0.23 for 212
Mann-Whitney U test between de novo and IEDB peptides). Furthermore, majority of the de 213 novo peptides were predicted as good binders by multiple criteria: 79.3% (4,220 / 5,320) weak-214 binding, 51.8% (2,757 / 5,320) strong-binding, and 74.0% (3,938 / 5,320) with binding affinity 215 less than 500 nM (Supplementary Figure S2) . Similar results were observed for de novo 216
peptides of different HLA-I alleles of the other four patients (Supplementary Figure S3 ). We also 217
applied GibbsCluster [23], an unsupervised alignment and clustering method to identify binding 218 motifs without the need of HLA allele information. We found that the de novo peptides of patient 219
Mel-15 were clustered into four groups of which motifs corresponded exactly to four alleles of 220 the patient (Figure 2h ). Note that both de novo sequencing and unsupervised clustering 221 methods do not use any prior knowledge such as protein database or HLA allele information, 222
yet their combination still revealed the correct binding motifs of the patient. This suggests that 223 our workflow can be used to identify novel HLA peptides of unknown alleles. Results from the 224 database peptides also yielded the same binding motifs (Supplementary Figure S4) . 225
Finally, we used an IEDB tool (http://tools.iedb.org/immunogenicity/) [24] to predict the 226 immunogenicity of de novo HLA-I peptides and then compared to database, IEDB, and human 227 immunogenic peptides that were used in that original study (Figure 2i ). We found that 38.8% 228
(2,065 / 5,320) of the de novo peptides had positive predicted immunogenicity (log-likelihood 229 ratio of immunogenic over non-immunogenic [24]). The de novo peptides had lower predicted 230 immunogenicity than the database and IEDB peptides, which in turn were less immunogenic 231 than the original peptides (Calis et al.) . This was expected because the tool had been 232 developed on a limited set of a few thousands well-studied peptides. The predicted 233 immunogenicity of de novo HLA-I peptides of the other four patients are provided in 234
Supplementary Figure S5 . 235
Overall, our analysis results confirmed the correctness, and more importantly, the essential 236 characteristics of de novo HLA peptides for immunotherapy. The remaining question is to select 237 candidate neoantigens from de novo HLA peptides based on their characteristics. 238
Neoantigen Selection and Evaluation 239
We considered several criteria that had been widely used in previous studies for neoantigen 240 selection [6-8, 13, 14, 21, 22] . Specifically, we checked whether a de novo HLA peptide carried 241 one amino acid substitution by aligning its sequence to the Swiss-Prot human protein database, 242
and whether that substitution was caused by one single nucleotide difference in the encoding 243 codon. In this paper, we refer to those substitutions as "missense-like mutations". For each 244 mutation, we recorded whether the wild-type peptide was also detected and whether the 245 mutated amino acid was located at a flanking position. For expression level information of a 246 peptide, we calculated the number of its PSMs, their total identification score, and their total 247 abundance. Finally, we used NetMHCpan and IEDB tools [10, 24] to predict the binding affinity 248 and the immunogenicity of a peptide. The results for 10,440 HLA-I and 1,585 HLA-II de novo 249 peptides of five patients are provided in Supplementary Table S3 . 250
To select candidate neoantigens, we focused on de novo HLA peptides that carried one single 251 missense-like mutation. This criterion reduced the number of peptides considerably, e.g. from 252
5,320 to 328 HLA-I and from 863 to 154 HLA-II peptides of patient Mel-15. We further filtered 253
out peptides with only one supporting PSM or with mutations at flanking positions because they 254
were more error-prone and less stable to be effective neoantigens. In average, we obtained 154 255
HLA-I and 47 HLA-II candidates per patient. Expression level, binding affinity, and 256
immunogenicity can be further used to prioritize candidates for experimental validation of 257 immune response; we avoided using those information as hard filters (Supplementary Table  258 S3). 259
We cross-checked our de novo HLA peptides against the nucleotide mutations and mRNA 260 transcripts in the original publication [13] . We identified seven HLA-I and ten HLA-II candidate 261
neoantigens that matched missense variants detected from exome sequencing (Tables 2 and  262 3). The first seven were among eleven neoantigens reported by the authors using a 263 proteogenomic approach that required both exome sequencing and proteomics database 264
search. Two HLA-I neoantigens, "GRIAFFLKY" and "KLILWRGLK", had been experimentally 265 validated to elicit specific T-cell responses. We indeed observed that those two peptides had 266 superior immunogenicity, and especially, expression level of up to one order of magnitude 267
higher than the other neoantigens (Table 2) . This observation confirms the critical role of 268 peptide-level expression for effective immunotherapy, in addition to immunogenicity and binding 269 affinity. 270
The ten HLA-II candidate neoantigens were novel and had not been reported in [13] . They were 271 clustered around a single missense mutation and were a good example to illustrate the 272 complicated digestion of HLA-II peptides ( Table 3) . Eight of them were predicted as strong 273
binders by NetMHCIIpan (rank <= 2%), two as weak binders (rank <= 10%). The peptide 274 located at the center of the cluster, "TSTRTYSLS SALRPS", showed both highest expression 275 level and binding affinity, thus representing a promising target for further experimental 276 validation. Interestingly, another peptide, "SLSSALRPSTSRSLY", showed up in both HLA-I and 277
HLA-II datasets with very high expression level (Tables 2 and 3 ). Using a consensus method of 278 multiple binding prediction tools from IEDB to double-check, we found that this peptide had a 279
binding affinity rank of 0.08%, instead of 4.5% as predicted by NetMHCIIpan, and exhibited a 280 different binding motif from the rest of the cluster. Thus, given its superior binding affinity and 281 expression level, this peptide would also represent a great candidate for immune response 282
validation. 283
We also investigated the four HLA-I neoantigens that had been reported in [13] but were not 284 detected by our method. Three of them were not supported by good PSMs, and in fact, 285
DeepNovo and PEAKS X identified alternative peptides that better matched the corresponding 286 spectra (Supplementary Figure S6) . The remaining neoantigen was missed due to a de novo 287 sequencing error. We noticed that all four peptides had been originally identified at 5% FDR 288 instead of 1%, so their signals were possibly too weak for identification. 289
DISCUSSION 290
In this study, we proposed a personalized de novo sequencing workflow to identify HLA 291 neoantigens directly and solely from mass spectrometry data. The key advantage of our method 292
is the ability of its deep learning model to adapt to a specific immunopeptidome of an individual 293 patient. This personalized approach greatly improved the performance of de novo sequencing 294 and allowed to accurately identify mutated HLA peptides. For instance, we showed that a 295 personalized model achieved up to 14.3% higher accuracy than a generic model, identified 296
38.9% more de novo peptides at 1% FDR, and doubled the number of validated neoantigens. 297
We applied the workflow to five melanoma patients and identified 10,440 HLA-I and 1,585 HLA-298
II de novo peptides at 1% FDR, expanding their immunopeptidomes by approximately 10%. Our 299 analysis also demonstrated that the de novo HLA peptides exhibited the same immune 300 characteristics as previously reported human epitopes, including binding affinity, 301
immunogenicity, and expression level, which are essential for effective immunotherapy. We 302 cross-checked our de novo HLA peptides against exome sequencing results and found ten 303
novel HLA-II neoantigens that had not been reported earlier. This result demonstrated the 304 capability of our de novo sequencing approach to overcome the challenges of unknown 305 digestion rules and binding prediction for HLA-II peptides. Last but not least, our de novo 306 sequencing workflow directly predicted neoantigens from mass spectrometry data and did not 307 require genome-level information nor HLA alleles of the patient as in existing approaches. Such 308 an independent approach allows to discover novel mutated peptides that might be difficult to 309 detect at the genome level, e.g. cis-and trans-spliced peptides. Thus, our personalized de novo 310 sequencing workflow to predict mutated peptides from the cancer cell surface presents a simple 311
and direct solution to discover neoantigens for cancer immunotherapy. As Newton said, "nature 312 is pleased with simplicity". 313 Binding affinity and immunogenicity information are not available for "SLSSALRPSTSRSLY" because this is actually an HLA-II, not HLA-I peptide.
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Binding affinity rank % Table 3 . HLA-II candidate neoantigens that matched to RNA-Seq results.
YVTTSTRTYSLS SALRPSTS
HLA: Human Leukocyte Antigen The mutated amino acid is underlined and highlighted in red for the reference (top row) and the neoantigens. This mutation site is located at Gly41Ser, transcript ENST00000224237, gene name VIM, patient Mel-15.
